Health Care: A core sector in portfolio construct


Health Care fits well in the secular growth theme of the CIO Barbell Strategy
Chief Investment Office27 Apr 2021
  • Health Care fits well in the secular growth theme of the CIO Barbell Strategy
Photo credit: AFP Photo


With its good long-term fundamentals, the sector has delivered solid earnings and share price performance since the start of the decade (Figure 1). We remain constructive on the fundamental outlook as the investment thesis remains intact.

Importantly, the Health Care sector experienced a lower level of gyrations over cycles in recent years (Figure 2). For investors looking to build a diversified, long-term portfolio and to capture superior growth, Health Care is a sector which should be included.

Over time, we expect the sector’s valuations to return to premium in reflection of the its unique and superb fundamentals, which include resilience in earnings, global reach, and the inexorable march of health care firms’ research and development (R&D) that expands the total addressable market (TAM), and the fundamental importance of health care to existing and future generations in the years ahead. The discovery of antivirals, new remedies, and their availability to the general public will reshape the global health care industry.

Figure 1: Positive secular trend…


Figure 2: …and lower gyrations within cycles


A structurally important sector. Health Care is among the top weighted sectors and accounts for more than 10% in the global benchmark, the MSCI World Equity Index (Figure 3). Its stable and secular growth characteristic allows it to be highly favoured by investors and we believe it is a must-have sector in portfolio construct.

 

The diversity and size of the Health Care sector makes it easy to be included in any portfolio construct. It comprises the following sub-sectors: Pharmaceutical, Equipment, Biotechnology, Managed Health Care, Life Sciences Tools, Services, Facility Management, and Supply Provisions (Figure 4).

Figure 3: Health Care is an important sector in a global context


Figure 4: Pharmaceutical, Equipment, and Biotechnology are the major sub-sectors, led by companies from developed nations

Ageing population ratio is a long term trend. Demand for medical attention and services is also caused by the rising ratio of the aged population globally. The world has 730m people at or above 65 years as at end-2020, equivalent to 9% of the global population (Figure 5). This number is projected to reach 930m by 2028, an increase of 27% over the next eight years. The mammoth size of this group, most of which are Baby Boomers, will boost the strong consumption of health care-related services and solutions.

Figure 5: Ageing population ratio climbing

Patented drugs leading the pack. Industry leaders are well ahead of the competition in new drug developments. Generic drugs accounted for less than 10% of total revenue share globally and are projected to stay within that range (Figure 6). The majority of the revenue share are still within tight grip of pharmaceutical companies with branded and orphan drugs.

It is projected that patented and orphan drugs will continue to command a combined 90% revenue market share globally in the years to come, alleviating the overblown concerns on patent cliff.

Figure 6: Generic drugs are not a threat

 

Outlook. The Health Care sector is set to deliver long-term sustainable growth due to:

1.      Ageing population and longer lifespan, giving rise to greater need for medical products and services.

2.      Rising disposable income and greater allocation of disposable income to medical expenditure.

3.      Continuous R&D leading to medical and technological advances, which expand the TAM in terms of treatment for more diseases and methods to better treat existing diseases

Recommendation. Health Care is a unique industry that will continue to enjoy stable revenue and earnings uptrend over economic cycles (Figure 7). This sector should be included as an integral part of a holistic long term core portfolio construct. Health Care stocks are trading at attractive valuations, with robust long-term earnings potential while being defensive in nature.

Since 2Q20, the valuation premium has reversed into a discount (Figure 8). We think this phenomenon should reverse as the sector consistently offers higher return on equity (ROE) than the global equities benchmark (Figure 9). 

Figure 7: Solid earnings trend


Figure 8: Valuation discount to global equities to narrow


Figure 9: Consistently better shareholder returns

The information published by DBS Bank Ltd. (company registration no.: 196800306E) (“DBS”) is for information only. It is based on information or opinions obtained from sources believed to be reliable (but which have not been independently verified by DBS, its related companies and affiliates (“DBS Group”)) and to the maximum extent permitted by law, DBS Group does not make any representation or warranty (express or implied) as to its accuracy, completeness, timeliness or correctness for any particular purpose. Opinions and estimates are subject to change without notice. The publication and distribution of the information does not constitute nor does it imply any form of endorsement by DBS Group of any person, entity, services or products described or appearing in the information. Any past performance, projection, forecast or simulation of results is not necessarily indicative of the future or likely performance of any investment or securities. Foreign exchange transactions involve risks. You should note that fluctuations in foreign exchange rates may result in losses. You may wish to seek your own independent financial, tax, or legal advice or make such independent investigations as you consider necessary or appropriate.

The information published is not and does not constitute or form part of any offer, recommendation, invitation or solicitation to subscribe to or to enter into any transaction; nor is it calculated to invite, nor does it permit the making of offers to the public to subscribe to or enter into any transaction in any jurisdiction or country in which such offer, recommendation, invitation or solicitation is not authorised or to any person to whom it is unlawful to make such offer, recommendation, invitation or solicitation or where such offer, recommendation, invitation or solicitation would be contrary to law or regulation or which would subject DBS Group to any registration requirement within such jurisdiction or country, and should not be viewed as such. Without prejudice to the generality of the foregoing, the information, services or products described or appearing in the information are not specifically intended for or specifically targeted at the public in any specific jurisdiction.

The information is the property of DBS and is protected by applicable intellectual property laws. No reproduction, transmission, sale, distribution, publication, broadcast, circulation, modification, dissemination, or commercial exploitation such information in any manner (including electronic, print or other media now known or hereafter developed) is permitted.

DBS Group and its respective directors, officers and/or employees may have positions or other interests in, and may effect transactions in securities mentioned and may also perform or seek to perform broking, investment banking and other banking or financial services to any persons or entities mentioned.

To the maximum extent permitted by law, DBS Group accepts no liability for any losses or damages (including direct, special, indirect, consequential, incidental or loss of profits) of any kind arising from or in connection with any reliance and/or use of the information (including any error, omission or misstatement, negligent or otherwise) or further communication, even if DBS Group has been advised of the possibility thereof.

The information is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation. The information is distributed (a) in Singapore, by DBS Bank Ltd.; (b) in China, by DBS Bank (China) Ltd; (c) in Hong Kong, by DBS Bank (Hong Kong) Limited; (d) in Taiwan, by DBS Bank (Taiwan) Ltd; (e) in Indonesia, by PT DBS Indonesia; and (f) in India, by DBS Bank Ltd, Mumbai Branch.